Major study reveals new ways to classify cancer
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...
List view / Grid view
News
Boehringer Ingelheim expands its production footprint in China
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
Genzyme’s multiple sclerosis franchise featured at ECTRIMS
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
European Commission approves Gilead Sciences’ Tybost™
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
Takeda submits new drug application in Japan for TAK-816
27 September 2013 | By Takeda Pharmaceutical Company Limited
TAK-816 is a Haemophilus Influenzae type b (Hib) vaccine...
EMA accepts AstraZeneca’s naloxegol marketing authorisation application
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
Teva presents new multiple sclerosis data 29th ECTRIMS Congress
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
Penn Pharma officially opens world leading contained manufacturing facility
26 September 2013 | By Penn Pharma
A £14 million state-of-the-art facility formally opened...
CRT Pioneer fund, BACIT and SAREUM agree to cancer drug funding
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
New Phase III data showed Dapagliflozin significantly reduced HbA1c compared to placebo
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
GSK receives marketing authorisation from the European Commission for additional Revolade™ (eltrombopag) indication
25 September 2013 | By GSK
European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection...
Enrolment of Victoza® (liraglutide) cardiovascular outcomes trial completed on schedule
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
Amgen And ShanghaiTech University announce plans for R&D center
25 September 2013 | By Amgen
Amgen And ShanghaiTech University agree plans for Amgen to open a China research and development (R&D) center at ShanghaiTech University...
Pfizer announces data for XELJANZ® (tofacitinib citrate) in rheumatoid arthritis
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
AbbVie and Galapagos to co-develop Cystic Fibrosis therapies
25 September 2013 | By AbbVie
Global alliance formed to discover, develop and commercialise novel potentiator and combination therapies in cystic fibrosis...
